{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:50:43Z","timestamp":1790182243456,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T00:00:00Z","timestamp":1579824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T00:00:00Z","timestamp":1579824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>Systemic mastocytosis (SM) is characterized by the expansion of clonal mast cells that infiltrate various organ systems. The extent of organ infiltration and subsequent organ damage distinguishes between indolent SM (ISM) defined by a nearly normal life expectancy and advanced SM (AdvSM) defined by poor prognosis. In ISM, measurement of the bone mineral density (BMD) frequently reveals osteoporosis. In contrast, the clinical implication of an increased BMD and osteosclerosis remains unclear.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>BMD was evaluated in 61 patients with mastocytosis (ISM, <jats:italic>n<\/jats:italic>\u2009=\u200929, 48%; AdvSM, <jats:italic>n<\/jats:italic>\u2009=\u200932, 52%). We correlated the prevalence of osteoporosis, increased BMD and osteosclerosis with clinical parameters, disease variant and prognosis.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Osteoporosis was detected in 11\/29 (38%) patients with ISM but only in 2\/32 (6%) patients with AdvSM (<jats:italic>p<\/jats:italic>\u2009=\u20090.004). An increased BMD was detected in 1\/29 (3%) patients with ISM and 24\/32 (75%) patients with AdvSM (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) while osteosclerosis was only detected in AdvSM patients (16\/32, 50%). AdvSM patients with increased BMD had higher levels of bone marrow mast cell infiltration, higher serum tryptase and alkaline phosphatase levels compared to ISM as well as higher number of high-molecular risk mutations (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). In addition, we found that the prognosis of AdvSM patients with increased BMD is inferior compared to those without increased BMD (median overall survival 3.6\u00a0years versus not reached, <jats:italic>p<\/jats:italic>\u2009=\u20090.031).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Osteoporosis is a common feature in ISM but not in AdvSM. An increased BMD is frequently present in AdvSM but not in ISM and is associated with more advanced disease and inferior outcome.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00432-019-03119-3","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T17:05:16Z","timestamp":1579885516000},"page":"945-951","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis"],"prefix":"10.1007","volume":"146","author":[{"given":"Philipp","family":"Riffel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Schwaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Naumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Metzgeroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Fabarius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan O.","family":"Schoenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Karsten","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9148-9398","authenticated-orcid":false,"given":"Mohamad","family":"Jawhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,24]]},"reference":[{"key":"3119_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"20","author":"DA Arber","year":"2016","unstructured":"Arber DA et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 20:2391\u20132405","journal-title":"Blood"},{"key":"3119_CR2","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1136\/ard.2009.124511","volume":"10","author":"S Barete","year":"2010","unstructured":"Barete S et al (2010) Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 10:1838\u20131841","journal-title":"Ann Rheum Dis"},{"key":"3119_CR3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1359\/jbmr.2002.17.4.567","volume":"4","author":"C Brumsen","year":"2002","unstructured":"Brumsen C et al (2002a) Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy. J Bone Miner Res 4:567\u2013569","journal-title":"J Bone Miner Res"},{"key":"3119_CR4","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S8756-3282(02)00875-X","volume":"5","author":"C Brumsen","year":"2002","unstructured":"Brumsen C et al (2002b) A potential role for the mast cell in the pathogenesis of idiopathic osteoporosis in men. Bone 5:556\u2013561","journal-title":"Bone"},{"key":"3119_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.semarthrit.2006.03.004","volume":"1","author":"N Chiappetta","year":"2006","unstructured":"Chiappetta N, Gruber B (2006) The role of mast cells in osteoporosis. Semin Arthritis Rheum 1:32\u201336","journal-title":"Semin Arthritis Rheum"},{"key":"3119_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00774-007-0800-x","volume":"2","author":"ML Donker","year":"2008","unstructured":"Donker ML et al (2008) Two patients with osteoporosis: initial presentation of systemic mastocytosis. J Bone Miner Metab 2:199\u2013202","journal-title":"J Bone Miner Metab"},{"key":"3119_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00002517-199109000-00016","volume":"3","author":"Y Floman","year":"1991","unstructured":"Floman Y, Amir G (1991) Systemic mastocytosis presenting with severe spinal osteopenia and multiple compression fractures. J Spinal Disord 3:369\u2013373","journal-title":"J Spinal Disord"},{"key":"3119_CR8","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/rheumatology\/ket007","volume":"6","author":"CL Gregson","year":"2013","unstructured":"Gregson CL et al (2013) Friend or foe: high bone mineral density on routine bone density scanning, a review of causes and management. Rheumatology (Oxford) 6:968\u2013985","journal-title":"Rheumatology (Oxford)"},{"key":"3119_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/8756-3282(89)90059-8","volume":"4","author":"JA Harvey","year":"1989","unstructured":"Harvey JA et al (1989) Osteoporosis associated with mastocytosis confined to bone: report of two cases. Bone 4:237\u2013241","journal-title":"Bone"},{"key":"3119_CR10","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S0046-8177(85)80252-5","volume":"8","author":"HP Horny","year":"1985","unstructured":"Horny HP et al (1985) Bone marrow findings in systemic mastocytosis. Hum Pathol 8:808\u2013814","journal-title":"Hum Pathol"},{"key":"3119_CR11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1259\/0007-1285-60-716-765","volume":"716","author":"TY Huang","year":"1987","unstructured":"Huang TY et al (1987) Radiological features of systemic mast-cell disease. Br J Radiol 716:765\u2013770","journal-title":"Br J Radiol"},{"key":"3119_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/leu.2015.4","volume":"5","author":"M Jawhar","year":"2015","unstructured":"Jawhar M et al (2015) Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. Leukemia 5:1115\u20131122","journal-title":"Leukemia"},{"key":"3119_CR13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/leu.2015.284","volume":"1","author":"M Jawhar","year":"2016","unstructured":"Jawhar M et al (2016) Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia 1:136\u2013143","journal-title":"Leukemia"},{"key":"3119_CR14","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3324\/haematol.2017.163964","volume":"6","author":"M Jawhar","year":"2017","unstructured":"Jawhar M et al (2017a) The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. Haematologica 6:1035\u20131043","journal-title":"Haematologica"},{"key":"3119_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","volume":"2","author":"M Jawhar","year":"2017","unstructured":"Jawhar M et al (2017b) Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood 2:137\u2013145","journal-title":"Blood"},{"key":"3119_CR16","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1200\/JCO.19.00640","volume":"31","author":"M Jawhar","year":"2019","unstructured":"Jawhar M et al (2019) MARS: mutation-adjusted risk score for advanced systemic mastocytosis. J Clin Oncol 31:2846\u20132856","journal-title":"J Clin Oncol"},{"key":"3119_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ageing\/25.1.1","volume":"1","author":"C Johansson","year":"1996","unstructured":"Johansson C et al (1996) Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing 1:1\u20137 (Johansson, 1996 #19)","journal-title":"Age Ageing"},{"key":"3119_CR18","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/BF01622200","volume":"6","author":"JA Kanis","year":"1994","unstructured":"Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 6:368\u2013381","journal-title":"Osteoporos Int"},{"key":"3119_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1159\/000091172","volume":"3","author":"NM Kushnir-Sukhov","year":"2006","unstructured":"Kushnir-Sukhov NM et al (2006) Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis. Int Arch Allergy Immunol 3:265\u2013270","journal-title":"Int Arch Allergy Immunol"},{"key":"3119_CR20","first-page":"97","volume":"1","author":"M Manara","year":"2010","unstructured":"Manara M et al (2010) Osteoporosis with vertebral fractures in young males, due to bone marrow mastocytosis: a report of two cases. Clin Exp Rheumatol 1:97\u2013100","journal-title":"Clin Exp Rheumatol"},{"key":"3119_CR21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s10067-009-1165-4","volume":"7","author":"R Mathew","year":"2009","unstructured":"Mathew R et al (2009) Systemic mastocytosis presenting as osteoporosis\u2014a case report. Clin Rheumatol 7:865\u2013866","journal-title":"Clin Rheumatol"},{"key":"3119_CR22","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","volume":"4","author":"DD Metcalfe","year":"2008","unstructured":"Metcalfe DD (2008) Mast cells and mastocytosis. Blood 4:946\u2013956","journal-title":"Blood"},{"key":"3119_CR23","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1007\/s00277-019-03826-4","volume":"98","author":"P Riffel","year":"2019","unstructured":"Riffel P et al (2019) Magnetic resonance imaging reveals distinct bone marrow patterns in indolent and advanced systemic mastocytosis. Ann Hematol 98:2693\u20132701","journal-title":"Ann Hematol"},{"key":"3119_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","volume":"1","author":"DE Rollison","year":"2008","unstructured":"Rollison DE et al (2008) Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs. Blood 1:45\u201352","journal-title":"Blood"},{"key":"3119_CR25","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.bone.2011.07.004","volume":"4","author":"M Rossini","year":"2011","unstructured":"Rossini M et al (2011) Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 4:880\u2013885","journal-title":"Bone"},{"key":"3119_CR26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.iac.2014.01.011","volume":"2","author":"M Rossini","year":"2014","unstructured":"Rossini M et al (2014) Bone involvement and osteoporosis in mastocytosis. Immunol Allergy Clin N Am 2:383\u2013396","journal-title":"Immunol Allergy Clin N Am"},{"key":"3119_CR27","doi-asserted-by":"publisher","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","volume":"6","author":"WR Sperr","year":"2019","unstructured":"Sperr WR et al (2019) International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematol 6:e638\u2013e649","journal-title":"Lancet Haematol"},{"key":"3119_CR28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","volume":"7","author":"P Valent","year":"2001","unstructured":"Valent P et al (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 7:603\u2013625","journal-title":"Leuk Res"},{"key":"3119_CR29","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","volume":"5","author":"P Valent","year":"2003","unstructured":"Valent P et al (2003) Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 5:695\u2013717","journal-title":"Br J Haematol"},{"key":"3119_CR30","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","volume":"6","author":"P Valent","year":"2007","unstructured":"Valent P et al (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 6:435\u2013453","journal-title":"Eur J Clin Invest"},{"key":"3119_CR31","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","volume":"11","author":"P Valent","year":"2017","unstructured":"Valent P et al (2017) Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 11:1420\u20131427","journal-title":"Blood"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-03119-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-019-03119-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-03119-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:32:58Z","timestamp":1611361978000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-019-03119-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,24]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["3119"],"URL":"https:\/\/doi.org\/10.1007\/s00432-019-03119-3","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,24]]},"assertion":[{"value":"15 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}